N. erin Et Al. , "CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.," 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy , Meinz, Germany, pp.1-2, 2016
erin, N. Et Al. 2016. CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.. 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy , (Meinz, Germany), 1-2.
erin, N., Podnos, A., TANRIÖVER, G., Prodeus, A., Garipey, J., & Gorczynski, R., (2016). CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response. . 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy (pp.1-2). Meinz, Germany
erin, NURAY Et Al. "CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.," 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy, Meinz, Germany, 2016
erin, NURAY Et Al. "CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.." 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy , Meinz, Germany, pp.1-2, 2016
erin, N. Et Al. (2016) . "CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.." 14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy , Meinz, Germany, pp.1-2.
@conferencepaper{conferencepaper, author={NURAY ERİN Et Al. }, title={CD200 mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carsinoma: Possible role of in vivo increased anti—tumoral immune response.}, congress name={14. CIMT Annual Meeting Mechanisms of efficacy in cancer immunotherapy}, city={Meinz}, country={Germany}, year={2016}, pages={1-2} }